<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81799">
  <stage>Registered</stage>
  <submitdate>10/01/2007</submitdate>
  <approvaldate>23/01/2007</approvaldate>
  <actrnumber>ACTRN12607000078459</actrnumber>
  <trial_identification>
    <studytitle>A phase Ia study of MRC202 in patients with malignant ascites caused by cancer.</studytitle>
    <scientifictitle>A phase Ia (pharmacokinetic) study of intraperitoneal MRC202 in patients with peritoneal cancer refractory to standard treatments.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Malignant ascites (hydoperitoneum) associated with cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an open label study of patients with malignant ascites.  The patients will initially have ascites drained.  A 1L dose (varying concetrations of either 800mg/L, 1600mg/L or 2000mg/L) of MRC202 will be administered, immediately following drainage, via an intraperitoneal catheter.  Patients will remain under observation for 4 weeks, after which a wash-out product will be administered.  Blood and peritoneal fluid will be sampled regularly (1, 2, 4, 6, 8, 24, 48, 96 hours and at the 4 week timepoint).</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine pharmakokinetics of MRC202 and sulfoxide metabolites</outcome>
      <timepoint>Sampling timepoints at 1, 2, 4, 6, 8, 24, 48 and 96 hours and 4 weeks after intraperitoneal administration.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Determine dose response to ensure it is within safety limits, as defined by Guidance on Good Clinical Practice (CPMP/ICH/135/95).</outcome>
      <timepoint>At 4 weeks over limited range of exposures </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Determine feasibility of intraperitoneal adminstration for MRC202.</outcome>
      <timepoint>End of Phase Ia trial</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine feasibility of : Vascular Endothelial Groth Factor (VEGF); circulating endothelial cells; and Vascular Cell Adhesion Molecule - 1 (VCAM) expression in blood and peritoneal fluid as markers of inhibition of angiogensis.</outcome>
      <timepoint>At sampling timepoints of 1, 2, 4, 6, 8, 24, 48 and 96 hours and 4 weeks after intraperitoneal administration.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically or cytologically proven advanced or metastatic cancer.Positive or suggestive peritoneal cytology.Judged likely to benefit from insertion of peritoneal port for symptom control.Must have measurable or evaluable disease.Ascites refractory to standard treatments.ECOG 0-3 performance status.At least 3 weeks since prior chemotherapy (at least 6 weeks from agents know to be toxic to stem cells)Must have recovered from reversible side effects of prior therapy.At least 2 weeks since any prior radiotherapy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unresolved ongoing infection requiring treatment.Decompensated liver disease with non-malignant ascites or coagulopathy or encephalopathy.Severe co-morbidity at the discretion of the investigatorsUnwilling or unable to have insertion of an intraperitoneal portacath.Pregnant or breast-feeding mothers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>10/02/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MRC Biotech Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Level 17, 201 Miller St
North Sydney, NSW, 2060</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>MRC Biotech Pty Ltd</fundingname>
      <fundingaddress>Level 17, 201 Miller St
North Sydney, NSW, 2060</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is aimed at evaluating the suitablility of MRC202 as a therapy for malignant ascites associated with cancer.  based on extensive animal studies MRC202 has been shown as potential an effective agent to slow or treat malignant ascites.  This initial study is aimed as determining an appropriate dose concentration.  Data from the study will be used to design a more comprehensive study assessing the efficacy of the drug.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. George Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/01/2007</ethicapprovaldate>
      <hrec>06/62 </hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Andrews</name>
      <address>MRC Biotech Pty Ltd
Level 17
201 Miller St
North Sydney NSW 2060</address>
      <phone>+61 2 89232561</phone>
      <fax />
      <email>david@mrcbiotech.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>David Andrews</name>
      <address>MRC Biotech Pty Ltd
Level 17
201 Miller St
North Sydney NSW 2060</address>
      <phone>+61 2 89232561</phone>
      <fax />
      <email>david@mrcbiotech.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>